Adapting Feasibility Tools to Specific Therapeutic Areas in Clinical Trials

Why Customization Matters in Feasibility Assessments

While feasibility questionnaires are a standard component of clinical trial planning, a “one-size-fits-all” approach often results in incomplete or misleading data. Different therapeutic areas present unique operational, regulatory, and recruitment challenges. Therefore, it is essential to adapt feasibility tools based on the specific clinical, procedural, and patient population characteristics of each therapeutic indication.

Regulatory agencies like the FDA and EMA expect feasibility efforts to align with study-specific complexities. For example, a Phase III oncology trial will have very different infrastructure and recruitment requirements compared to a vaccine study or a dermatology trial. Customization ensures that the sponsor gathers high-fidelity, indication-specific data, which reduces trial delays, improves protocol adherence, and enhances inspection readiness.

In this tutorial, we explore how sponsors and CROs can develop and deploy feasibility tools tailored to therapeutic areas including oncology, cardiology, infectious diseases, CNS disorders, and rare diseases.

Key Variables Differentiating Therapeutic Areas

Each therapeutic area involves unique variables that influence trial feasibility, including:

• Diagnostic criteria and screening processes
• Specialized equipment and lab tests
• Patient population size and disease prevalence
• Eligibility complexity and inclusion/exclusion criteria
• Site specialization and investigator qualifications

For example, an oncology trial may require immunohistochemistry, genetic sequencing, and radiologic assessments, while a vaccine trial may emphasize storage conditions for biologics and capacity for large-scale subject screening. Failing to account for these differences can lead to underperformance and protocol deviations.

Customizing Feasibility Tools in Oncology Trials

Oncology trials are often complex, with multiple arms, biomarker-based eligibility, and long treatment durations. Therefore, feasibility tools must address:

• Availability of tissue samples for biomarker testing
• Access to imaging facilities for RECIST-based assessments
• Experience in handling cytotoxic agents and managing SAE reporting
• Supportive care services like transfusion, nutrition, and palliative care

Below is a sample customization framework for oncology feasibility:

Oncology sites must also demonstrate access to multidisciplinary tumor boards, availability of radiology archiving systems, and electronic SAE tracking tools such as Argus Safety. To cross-reference recruitment and prior site experience, sponsors may consult the EU Clinical Trials Register.

Adapting Feasibility for Cardiovascular Trials

Cardiology studies may involve device implantation, ECG monitoring, and stress testing. In such cases, feasibility tools must capture:

• Availability of validated ECG and echocardiogram equipment
• GCP training in cardiovascular endpoints (e.g., MACE criteria)
• Presence of a catheterization lab or interventional cardiologist
• Patient adherence history in hypertension or dyslipidemia trials

Sample values might include:

• Validated ECG machine model: GE MAC 5500
• Calibration certificate date: June 2025
• Cardiology sub-investigator GCP completion: March 2024

Moreover, cardiology trials may need precise documentation of concomitant medications and lifestyle interventions. Questionnaires must be adapted to capture these site competencies.

Feasibility Tools for Infectious Disease Trials

Infectious disease trials—especially in vaccines or antimicrobial resistance studies—require a different set of site capabilities. Sponsors must customize feasibility questionnaires to capture:

• Cold-chain infrastructure for biologics (2–8°C and -20°C storage)
• Experience with biosafety level (BSL-2 or BSL-3) laboratory handling
• Regulatory familiarity with expedited review processes (e.g., EUA)
• Access to outbreak-prone communities or travel clinics

Feasibility templates for such trials often include verification of:

Sites that have participated in past epidemic response trials (e.g., COVID-19, H1N1) often score higher in feasibility assessments due to institutional readiness and protocol familiarity.

Feasibility Considerations in CNS Trials

CNS trials for indications like Alzheimer’s, Parkinson’s, or depression bring unique recruitment and assessment challenges. Key customization points include:

• Site capability for neurocognitive assessments (e.g., MMSE, MoCA)
• Investigator training in psychiatric or neurologic scales
• Caregiver consent handling for dementia patients
• Experience with long-term follow-up visits (≥12 months)

Example question: “Is your site trained in administering ADAS-Cog or CDR-SB assessments for Alzheimer’s patients?”

Feasibility tools must also factor in patient adherence barriers, comorbidities, and ability to comply with imaging and lab visit schedules. CNS studies often suffer from high dropout rates, so feasibility assessments should include questions on patient retention strategies.

Special Feasibility Approaches in Rare Disease Trials

Rare disease studies are constrained by extremely small patient populations. Feasibility tools in this context must go beyond traditional metrics and emphasize:

• Site access to patient registries or genetic databases
• Partnerships with advocacy groups or KOL networks
• Willingness to enroll non-local patients (e.g., travel support programs)
• Experience in adaptive trial designs and expanded access protocols

Due to ultra-orphan populations, sponsors may consider virtual or decentralized feasibility approaches, integrating telemedicine and remote monitoring tools. Additionally, feasibility questionnaires should include sections on protocol flexibility and site logistics for rare disease patients traveling long distances.

Best Practices for Implementing Customized Tools

To deploy customized feasibility tools effectively:

• Develop therapeutic area-specific templates reviewed by KOLs
• Pre-fill public domain data (e.g., IRB timelines) to reduce site burden
• Digitize questionnaires using secure platforms integrated with CTMS
• Score site responses using indication-weighted algorithms
• Train feasibility teams on therapeutic-specific nuances

Some organizations maintain a Feasibility SOP that includes annexures for oncology, cardiology, etc., ensuring consistency while allowing adaptation. For sponsors working with multiple CROs, standardizing customized tools via cross-functional working groups is recommended.

Conclusion

Feasibility tool customization is a regulatory, scientific, and operational imperative. Generic questionnaires can no longer capture the complexity of modern trials across diverse therapeutic areas. By developing indication-specific tools—grounded in real-world data, infrastructure requirements, and investigator qualifications—sponsors can enhance patient recruitment, ensure compliance, and minimize protocol deviations. With global trials becoming more complex, therapeutic customization of feasibility tools is essential for success in today’s regulatory environment.